The Patient-Centered Outcomes Research Institute is pleased to announce the following Town Hall meetings to publicize funding opportunities and application processes.
Read more about or Register for any of these events at: Upcoming Events
The program will include presentations from CRHMV investigators on human movement variability and its relationship with diseases such as Autism, Chronic Obstructive Pulmonary Disease, Stroke, Peripheral Arterial Disease, and others.
When: May 13, 2015
Who: Faculty, Postdocs, and Students
Meeting Information: http://www.unomaha.edu/college-of-education/cobre/community-engagement/research-day.php
The program’s highlight will be a keynote lecture by Dr. Karl Newell, Associate Dean for Research, University of Georgia. Dr. Newell’s research interests lie in the area of human movement in general and more specifically in motor learning and control. His research focuses on the coordination, control and skill of normal and abnormal human movement across the lifespan; intellectual disabilities and development of motor skills; and, drug and exercise influences on movement control. One of his major themes of research is motor learning across the life span with an emphasis on the information for and dynamics of change in coordination, control and skill of learning and development. The other major theme of his research is the study of variability in human movement and posture with specific reference to the onset of aging and Parkinson’s disease. His research has been essentially continuously funded with much of this support coming from NIH and NSF.
The organizers also encourage faculty, postdocs, and students to present scientific posters during the meeting relating to human movement. A dedicated unopposed time for the scientific posters will be provided in the program. Awards for posters will also be given at the social immediately following the keynote speaker. Meeting information is available through the CRHMV
A New Paradigm for Engaging the War on Infectious Diseases
February 17, 2015, Noon
Durham Research Center Auditorium
From the 1950s through the 1970s, the success of antibiotics and vaccines in controlling or eradicating infectious diseases (ID) worldwide resulted in decreased emphasis on development of ID vaccines and therapeutics. The emergence in the past three decades of the potential for bioterrorist attacks as well as emerging diseases such as SARS, West Nile, avian flu, swine flu, Ebola, has reversed this trend and renewed interest in treatment and prophylaxis of ID. Unfortunately, since potential sales of therapeutics for bioterrorist pathogens are limited mainly to orders for government stockpiles (e.g., anthrax, smallpox, botulinum toxin), and the development cost is high, traditional large pharmaceutical companies have cut back R&D resources in this arena. To combat this investment shortfall, a new paradigm has emerged where public-private partnerships between the NIH, DOD, World Health Organization, private foundations, academia, and non-profits, are beginning to function like pharmaceutical companies to advance the development of promising ID drugs, even when there is little opportunity for profit. This talk will discuss the growing need for ID vaccines and therapeutics, present new models for discovering and developing them, and provide examples of public-private partnerships that have advanced therapeutics for specific infectious diseases.
Dr. Jon C. Mirsalis, Ph.D., D.A.B.T., is Managing Director of the Biosciences Division and Executive Director of Translational Development at SRI International in Menlo Park, CA. Dr. Mirsalis is an internationally recognized expert in the development of drugs for infectious diseases.